SPRC SciSparc advances mdma-N-acylethanolamines IP for PTSD
SPRC SciSparc and NeuroThera/ClearMind collaboration advances mdma-N-acylethanolamines intellectual property for the treatment of PTSD, amid rising U.S. federal support for psychedelic innovation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.